A clinical-stage biotechnology company focused on discovering and developing antibody-based therapeutics derived from human immune responses. Its platform analyzes B‑cell immune repertoires to identify potential drug candidates, with programs historically targeting oncology and infectious diseases. ...
1 member of Congress has disclosed 2 trades in Atreca, Inc. (BCEL), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-11-08 | Christopher L. Jacobs | sell | $1K – $15K |
| 2022-06-16 | Christopher L. Jacobs | buy | $15K – $50K |